Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
JMIR Formative Research|June 4, 2024
Telemedicine With Wearable Technologies in Patients Undergoing Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy (TEL-HEMATO Study): Prospective Noninterventional Single-Center StudyLidia Hurtado, Melinda Gonzalez Concepcion, Aida Flix-Valle, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 10, 2018
Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous SystemJulia Garcia-Reyero, Nerea Martinez Magunacelaya, Ainara Gonzalez Pereña, et al.
Neurology|February 5, 2022
Pearls & Oy-sters: Arteriovenous Malformation With Sinus Thrombosis and Thalamic Hemorrhage: Unusual Cause of Parkinsonism and DementiaPatricia Rodrigo Armenteros, Solange Kapetanovic, Sonia Gonzalez Lopez, et al.
Journal of Clinical Pathology|January 26, 2020
Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGSJulia Garcia-Reyero, Nerea Martinez Magunacelaya, Sonia Gonzalez de Villambrosia, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 1, 2016
Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1Santiago Montes-Moreno, Nerea Martinez-Magunacelaya, Tomás Zecchini-Barrese, et al.
Haematologica|April 11, 2020
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphomaJulia Garcia-Reyero, Nerea Martinez Magunacelaya, Sonia Gonzalez de Villambrosia, et al.
British Journal of Haematology|December 19, 2014
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA GroupNoelia Purroy, Juan Bergua, Laura Gallur, et al.
Leukemia & Lymphoma|September 13, 2021
<i>BCL2</i> translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survivalSonia Gonzalez de Villambrosia, Mariana Bastos, Javier Menarguez Palanca, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 1, 2026
Comparative effectiveness of two alternative dosing strategies of pembrolizumab in metastatic non-small-cell lung cancer in a real-world settingMargarita Garrido-Siles, Jose Carlos Benitez, Elena Alvaro Sanz, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2025
Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent StudiesPhilippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, et al.
Pageof 5